| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Rheumatology, Washington University School of Medicine, St. Louis, MO 63110
Membrane cofactor protein (MCP; CD46) is a type 1 membrane glycoprotein that inhibits complement activation on host cells. It also is a measles virus (MV) receptor, an adherence factor for group A Streptococcus pyogenes, and a cellular pilus receptor for pathogenic Neisseria. The amino terminus of MCP consists of four complement control protein (CCP) repeats, three of which (CCP-1, -2, and -4) possess N-glycans. Immediately following the CCP modules is an alternatively spliced region for extensive O-glycosylation (termed the STP domain). Previous studies established that the N-glycan of CCP-2 is essential for MV binding and infection and that the splicing variants of the STP domain not only affect MV binding and fusion, but also differentially protect against complement-mediated cytolysis. In this report, we dissect the role of these carbohydrates on complement regulatory function. We constructed, expressed, and characterized proteins deleting these carbohydrates. For MCP-mediated protection against cytolysis, the N-glycans of CCP-2 and -4 were necessary, the STP segment influenced but was not essential, and the N-glycan of CCP-1 was not required. In addition, the rate and magnitude of cell surface cleavage of C4b to C4c and C4d by MCP and factor I correlated with cytoprotection. These studies expand the structure-function understanding of the active sites of MCP and elucidate an important role for carbohydrates in its function, a finding consistent with their conservation in the MCP of other species.
This article has been cited by other articles:
|
|
 |
|
  M. K. Liszewski, P. Bertram, M. K. Leung, R. Hauhart, L. Zhang, and J. P. Atkinson Smallpox Inhibitor of Complement Enzymes (SPICE): Regulation of Complement Activation on Cells and Mechanism of Its Cellular Attachment J. Immunol., September 15, 2008; 181(6): 4199 - 4207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fang, V. Fremeaux-Bacchi, M. K. Liszewski, G. Pianetti, M. Noris, T. H. J. Goodship, and J. P. Atkinson Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome Blood, January 15, 2008; 111(2): 624 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ram, J. Ngampasutadol, A. D. Cox, A. M. Blom, L. A. Lewis, F. St. Michael, J. Stupak, S. Gulati, and P. A. Rice Heptose I Glycan Substitutions on Neisseria gonorrhoeae Lipooligosaccharide Influence C4b-Binding Protein Binding and Serum Resistance Infect. Immun., August 1, 2007; 75(8): 4071 - 4081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Servais, V. Fremeaux-Bacchi, M. Lequintrec, R. Salomon, J. Blouin, B. Knebelmann, J.-P. Grunfeld, P. Lesavre, L.-H. Noel, and F. Fakhouri Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome J. Med. Genet., March 1, 2007; 44(3): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Caprioli, M. Noris, S. Brioschi, G. Pianetti, F. Castelletti, P. Bettinaglio, C. Mele, E. Bresin, L. Cassis, S. Gamba, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood, August 15, 2006; 108(4): 1267 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fremeaux-Bacchi, E. A. Moulton, D. Kavanagh, M.-A. Dragon-Durey, J. Blouin, A. Caudy, N. Arzouk, R. Cleper, M. Francois, G. Guest, et al. Genetic and Functional Analyses of Membrane Cofactor Protein (CD46) Mutations in Atypical Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2017 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Liszewski, M. K. Leung, R. Hauhart, R. M. L. Buller, P. Bertram, X. Wang, A. M. Rosengard, G. J. Kotwal, and J. P. Atkinson Structure and Regulatory Profile of the Monkeypox Inhibitor of Complement: Comparison to Homologs in Vaccinia and Variola and Evidence for Dimer Formation J. Immunol., March 15, 2006; 176(6): 3725 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Richards, E. J. Kemp, M. K. Liszewski, J. A. Goodship, A. K. Lampe, R. Decorte, M. H. Muslumanogglu, S. Kavukcu, G. Filler, Y. Pirson, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome PNAS, October 28, 2003; 100(22): 12966 - 12971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Barilla-LaBarca, M. K. Liszewski, J. D. Lambris, D. Hourcade, and J. P. Atkinson Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells J. Immunol., June 15, 2002; 168(12): 6298 - 6304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ram, M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, B. G. Monks, C. O'Connell, R. Boden, C. Elkins, M. K. Pangburn, et al. Binding of C4b-binding Protein to Porin: A Molecular Mechanism of Serum Resistance of Neisseria gonorrhoeae J. Exp. Med., January 29, 2001; 193(3): 281 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wang, M. K. Liszewski, A. C. Chan, and J. P. Atkinson Membrane Cofactor Protein (MCP; CD46): Isoform-Specific Tyrosine Phosphorylation J. Immunol., February 15, 2000; 164(4): 1839 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Liszewski, M. Leung, W. Cui, V. B. Subramanian, J. Parkinson, P. N. Barlow, M. Manchester, and J. P. Atkinson Dissecting Sites Important for Complement Regulatory Activity in Membrane Cofactor Protein (MCP; CD46) J. Biol. Chem., November 22, 2000; 275(48): 37692 - 37701. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
